TREATMENT OF HAIRY-CELL LEUKEMIA WITH 2-CHLORODEOXYADENOSINE VIA THE GROUP-C PROTOCOL MECHANISM OF THE NATIONAL-CANCER-INSTITUTE - A REPORTOF 979 PATIENTS

Citation
Bd. Cheson et al., TREATMENT OF HAIRY-CELL LEUKEMIA WITH 2-CHLORODEOXYADENOSINE VIA THE GROUP-C PROTOCOL MECHANISM OF THE NATIONAL-CANCER-INSTITUTE - A REPORTOF 979 PATIENTS, Journal of clinical oncology, 16(9), 1998, pp. 3007-3015
Citations number
36
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Oncology
ISSN journal
0732-183X
Volume
16
Issue
9
Year of publication
1998
Pages
3007 - 3015
Database
ISI
SICI code
0732-183X(1998)16:9<3007:TOHLW2>2.0.ZU;2-Y
Abstract
Purpose: To provide cladribine (CdA) to physicians for the treatment o f patients with previously treated or untreated hairy cell leukemia (H CL), and to determine the response rate, response duration, survival, and toxicity with this agent. Patients and Methods: This Group C phase II study was open to all eligible patients whose primary physician ob tained written permission from the National Cancer Institute (NCI) to register patients onto this protocol. Of 979 patients registered, 861 were assessable for response and 895 for toxicity, Results: The comple te remission (CR) rate was 50% and the partial remission (PR) rate was 37%. At a median follow-vp of 52 months, 12% of patients were reporte d to have progressed and 62 (7%) have died of disease. Conclusion: Thi s large experience confirms the excellent response rates and remission duration of CdA in patients with HCL. Nevertheless, the response rate s in this setting, which approximates general clinical practice, were lower than in other series. In general, CdA was well tolerated, but th e potential increased risk for secondary malignancies requires additio nal bellow-up evaluation. CdA can now be considered as one of the best agents for the treatment of HCL.